On February 7, 2018, The Burlington Free interviewed Emily Tarleton, Ph.D., bionutrition research manager at the UVM Clinical Research Center, about a recent clinical trial conducted at the College relating to use of magnesium for treatment of mild to moderate depression.
/home-page-images/tarleton_emily_(1).jpg?sfvrsn=f3d19f53_0)
Emily Tarleton, Ph.D., UVM bionutrition research manager
On February 7, 2018,
The Burlington Free Press highlighted recent work by UVM Larner College of Medicine's Emily Tarleton, Ph.D., the bionutrition research manager at the UVM Clinical Research Center. Tarleton is currently leading a clinical trial to determine whether supplemental magnesium influences symptoms of depression. The trial points to magnesium as a potential "safe, effective, and less expensive treatment option for mild to moderate depression." "...We found that over a six-week period of time, symptoms of both depression and anxiety improved significantly," said Tarleton, "And this was the case regardless of age, gender, baseline severity of depression, baseline magnesium status, or use of other treatments for depression, such as counseling or antidepressants."
Read the full interview and learn more about the trial and its findings
here.
Find out more on
The Odyssey and
Before It's News.